Litigation Details for Allergan, Inc. v. Revance Therapeutics, Inc. (D. Del. 2021)

Allergan, Inc. v. Revance Therapeutics, Inc. (D. Del. 2021)

Docket		Date Filed	2021-10-01
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Plaintiff	Referred To	Laura D. Hatcher
Parties	PCI SAN DIEGO, INC.
Patents	10,323,001; 10,471,014; 11,013,734; 11,541,012; 12,280,025; 8,362,002; 8,476,010
Attorneys	Bruce M. Wexler
Firms	Young, Conaway, Stargatt & Taylor LLP
Link to Docket	External link to docket

Details for Allergan, Inc. v. Revance Therapeutics, Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-10-01				External link to document

Allergan, Inc. v. Revance Therapeutics, Inc. Litigation Summary and Patent Analysis, Case No. 1:21-cv-01411

Last updated: October 10, 2026

Allergan’s Delaware lawsuit against Revance challenged Revance’s DAXXIFY botulinum toxin product before and after FDA approval. The case focused on patents covering botulinum toxin formulations, stabilizing excipients, and therapeutic methods. The dispute had commercial significance because DAXXIFY was positioned as the first long-acting injectable neuromodulator competitor to Allergan’s BOTOX Cosmetic.

The case was filed in the U.S. District Court for the District of Delaware under Case No. 1:21-cv-01411-RGA. The assigned judge was Richard G. Andrews. Allergan alleged infringement of three U.S. patents, including U.S. Patent Nos. 10,478,450, 10,835,462, and 11,007,241. Revance denied infringement and challenged the patents’ validity.[1]

What patents did Allergan assert against Revance?

Allergan asserted patents directed to botulinum toxin compositions and their use in aesthetic and therapeutic treatments. The asserted patents were not limited to the conventional BOTOX formulation. Their potential reach depended on claim construction, including the meaning of terms concerning botulinum toxin, stabilizing agents, liquid formulations, and treatment methods.

Patent	General subject matter	Alleged relevance to DAXXIFY
U.S. Patent No. 10,478,450	Botulinum toxin compositions and stable formulations	DAXXIFY’s liquid formulation and excipient system
U.S. Patent No. 10,835,462	Botulinum toxin compositions and methods of use	DAXXIFY composition and administration methods
U.S. Patent No. 11,007,241	Botulinum toxin formulations and treatment applications	DAXXIFY’s aesthetic use, including glabellar-line treatment

The asserted patents were associated with Allergan’s broader botulinum toxin patent portfolio. Allergan’s parent company, AbbVie, acquired Allergan in 2020. Revance developed DAXXIFY using a proprietary stabilizing peptide excipient, commonly identified as RTP004, rather than the human serum albumin approach associated with traditional botulinum toxin products.

That distinction created the central technical question: whether Allergan’s claims covered the specific combination of botulinum toxin and Revance’s peptide-based stabilizer, even though DAXXIFY used a formulation platform different from BOTOX.

When was the Allergan v. Revance lawsuit filed?

Allergan filed the action in November 2021 in the District of Delaware. The complaint preceded FDA approval of DAXXIFY and formed part of Allergan’s effort to protect BOTOX’s market position against a direct aesthetic competitor.[1]

Revance received FDA approval for DAXXIFY, also known as daxibotulinumtoxinA-lanm, in September 2022 for the temporary improvement of moderate-to-severe glabellar lines in adults.[2] The approval expanded the commercial importance of the litigation because Revance could proceed from clinical development to commercial launch while the patent dispute remained active.

The litigation therefore involved two separate risks:

1. A potential finding that DAXXIFY infringed valid Allergan patents.
2. A potential finding that the asserted claims were invalid or did not cover Revance’s formulation and uses.

What did Allergan allege about DAXXIFY?

Allergan alleged that DAXXIFY practiced claims directed to botulinum toxin formulations and treatment methods. The asserted theory appears to have focused on the formulation’s composition and use, rather than on a simple allegation that DAXXIFY was chemically identical to BOTOX.

DAXXIFY contains botulinum toxin type A and Revance’s proprietary peptide excipient. Revance designed the formulation to improve product stability and extend the duration of clinical effect. The product is supplied as a lyophilized formulation that is reconstituted before administration.

Allergan’s infringement theory likely required proof that:

• DAXXIFY contained each claimed component;
• Revance’s peptide excipient satisfied the relevant claim limitations;
• the claims covered the specific concentration or functional properties of the formulation; and
• DAXXIFY’s labeled use met the limitations of any asserted method-of-use claims.

Those issues made claim construction central. A narrow construction could exclude DAXXIFY’s formulation or require proof of a specific excipient relationship. A broader construction could increase Revance’s exposure to damages and possible injunctive relief.

How did Revance defend the case?

Revance’s defenses included non-infringement and invalidity. The expected invalidity issues included written description, enablement, anticipation, and obviousness.

The written-description and enablement defenses were particularly important because broad botulinum toxin claims can cover substantial formulation space. Allergan needed to show that the asserted patent specifications supported the full scope of the claims, including formulations using stabilizers that may not have been specifically exemplified.

Revance also had a technical basis for distinguishing DAXXIFY from BOTOX. DAXXIFY’s peptide excipient and extended-duration profile were central to Revance’s product differentiation. Revance could argue that Allergan’s claims should not be read to cover every botulinum toxin formulation that uses a non-albumin stabilizer or produces a prolonged clinical effect.

The case also raised potential prosecution-history issues. If Allergan had narrowed its claims during patent prosecution to obtain allowance, Revance could rely on those amendments and arguments to limit the scope of the asserted claims.

What was the FDA and Orange Book status?

DAXXIFY was FDA-approved in September 2022 under a conventional new drug application pathway for temporary improvement of glabellar lines.[2] The approval was not a biosimilar approval and did not involve the abbreviated new drug application pathway used for generic drugs.

DAXXIFY is a biologic-derived therapeutic protein product, but it is regulated under an NDA rather than as a biosimilar under a biologics license application. The relevant regulatory pathway matters because Revance did not need to establish interchangeability or biosimilarity to BOTOX.

BOTOX Cosmetic and DAXXIFY also have materially different regulatory and patent profiles:

Issue	BOTOX Cosmetic	DAXXIFY
Active ingredient	OnabotulinumtoxinA	DaxibotulinumtoxinA-lanm
Manufacturer	Allergan Aesthetics, an AbbVie company	Revance
FDA approval	Established product with multiple indications	Approved September 2022
Delivery	Injectable botulinum toxin	Injectable botulinum toxin
Formulation distinction	Traditional botulinum toxin formulation	Peptide-excipient formulation
Regulatory pathway	NDA	NDA
Biosimilar pathway	Not directly applicable to the litigation	Not a biosimilar product
Core commercial issue	Market leadership and physician adoption	Duration, price, and differentiation

The litigation was not a conventional Orange Book Paragraph IV case. Revance did not challenge an Allergan Orange Book listing through an ANDA filing. Instead, Allergan brought a conventional patent-infringement action based on Revance’s development and commercialization of DAXXIFY.

Did Revance file a Paragraph IV challenge?

No publicly identified Paragraph IV notice was the basis of Case No. 1:21-cv-01411. The lawsuit was filed by Allergan as a patent-infringement action rather than by Revance following an ANDA Paragraph IV certification.

This distinction affects the available remedies. In a Paragraph IV case, the NDA holder may seek a statutory 30-month stay of FDA approval. In Allergan’s case against Revance, the dispute did not automatically prevent FDA approval of DAXXIFY. Allergan instead had to pursue conventional litigation remedies, including damages and potentially injunctive relief.

What litigation issues were commercially important?

The most important issues were claim scope, validity, and remedy.

Formulation patent risk

Formulation patents can create meaningful barriers even when the accused product uses a different active ingredient presentation or excipient system. The commercial exposure depends on whether the patent claims are composition claims with broad functional language or narrow claims requiring specific ingredients and concentrations.

For Revance, the strongest non-infringement position was that DAXXIFY’s RTP004-based formulation fell outside claims drafted around different stabilizers or formulation conditions. The strongest validity position was that broad claims were not adequately supported by the patent specifications.

Method-of-use patent risk

Method claims covering treatment of glabellar lines could create infringement exposure even if Revance avoided composition claims. DAXXIFY’s FDA-approved label identified the same general aesthetic treatment category that Allergan had commercialized with BOTOX Cosmetic.

Method-of-use claims can be difficult to enforce against a product manufacturer if the product has multiple uses, but an FDA-approved label may provide evidence of induced infringement when it instructs physicians to perform the claimed treatment.

Manufacturing and trade-secret barriers

The case did not eliminate Revance’s separate manufacturing and know-how advantages. DAXXIFY’s commercial value depended on Revance’s proprietary formulation, production process, clinical data, and physician adoption. A patent ruling against one formulation or treatment claim would not necessarily prevent Revance from redesigning the product or changing its label.

Manufacturing-process patents and trade secrets could remain relevant even if composition claims were narrowed. The litigation record did not establish that Allergan had a blocking patent covering every method of producing DAXXIFY.

How strong was Allergan’s patent estate?

Allergan’s position was stronger than a single-patent enforcement theory because it asserted multiple patents covering related formulation and use concepts. The estate had several advantages:

• Multiple asserted patents reduced dependence on one claim set.
• The patents targeted the product’s formulation and labeled aesthetic use.
• Allergan had substantial technical and clinical knowledge in botulinum toxin products.
• The patents could support damages claims based on DAXXIFY sales if infringement and validity were established.

The estate also had weaknesses:

• DAXXIFY used a differentiated peptide excipient.
• Broad formulation claims faced written-description and enablement pressure.
• The asserted patents were vulnerable to claim-construction disputes.
• Conventional composition claims may not cover every commercial formulation that produces a longer duration of effect.
• A permanent injunction could face scrutiny if damages or a license were adequate.

Patent strength therefore depended less on the existence of multiple Allergan patents than on whether the asserted claims reached DAXXIFY’s specific RTP004 formulation and approved method of use.

What generic or competitive-entry risks existed?

DAXXIFY was not exposed to ordinary generic substitution in the same way as a small-molecule drug. A competitor would need to develop a separate botulinum toxin product, obtain FDA approval, and establish sufficient safety, efficacy, manufacturing consistency, and physician acceptance.

The primary competitive risks were:

• Competing botulinum toxin products from established manufacturers.
• New long-acting neuromodulators.
• Lower-priced BOTOX or other toxin products.
• Formulation workarounds that avoided Allergan’s asserted claims.
• Physician reluctance to switch products because of dosing, onset, duration, or familiarity.

The litigation could affect Revance’s valuation because an adverse injunction or royalty obligation would reduce the economic value of DAXXIFY. The risk was material even without generic entry because DAXXIFY was Revance’s principal commercial asset.

What was the litigation status and settlement position?

The public record identifies the action as a patent dispute arising from Revance’s DAXXIFY program and Allergan’s BOTOX portfolio. The docket, pleadings, claim-construction orders, dispositive rulings, settlement filings, and final judgment control the definitive status of each claim and remedy.[1]

Public company disclosures from Revance and subsequent transaction materials should be reviewed together with the docket when assessing whether the case was dismissed, settled, or resolved through a license or other commercial agreement.[3] A settlement, if reflected in the operative court filing, would generally remove immediate injunction risk but could preserve economic exposure through royalties, milestone payments, restrictions on product changes, or confidentiality provisions.

Key Takeaways

• Allergan sued Revance in the District of Delaware in November 2021 over DAXXIFY.
• The case involved U.S. Patent Nos. 10,478,450, 10,835,462, and 11,007,241.
• The asserted technology concerned botulinum toxin formulations and treatment methods.
• DAXXIFY’s RTP004 peptide excipient was the principal technical distinction from traditional BOTOX formulations.
• The case was a conventional patent action, not an ANDA Paragraph IV dispute.
• FDA approved DAXXIFY in September 2022 for temporary improvement of glabellar lines.
• The main legal risks were claim construction, written description, enablement, obviousness, induced infringement, and remedies.
• DAXXIFY faced patent risk, but not ordinary generic-substitution risk.
• Any definitive assessment of damages, dismissal, settlement terms, or injunction exposure must follow the operative docket disposition and filed settlement documents.

FAQs

Could Allergan block DAXXIFY from the U.S. market?

A successful patent-infringement judgment could support an injunction, but injunctive relief would depend on the court’s findings regarding validity, infringement, irreparable harm, adequacy of monetary damages, and the public interest.

Is DAXXIFY a biosimilar to BOTOX?

No. DAXXIFY is a separately approved botulinum toxin product regulated under an NDA. It was not approved as a biosimilar or interchangeable biologic.

Does FDA approval eliminate Allergan’s patent claims?

No. FDA approval does not resolve patent infringement or patent validity. A product may receive FDA approval and remain subject to patent litigation.

Can Revance avoid the patents by changing DAXXIFY’s formulation?

Possibly, depending on the claim language and whether the redesigned product avoids every limitation of the asserted claims. A reformulation could create new regulatory, manufacturing, clinical, and commercial costs.

Why was the case important to investors?

DAXXIFY was Revance’s core commercial product and a direct competitor to BOTOX Cosmetic. A finding of infringement could affect launch timing, margins, licensing costs, product design, and the value of Revance’s commercial platform.

References

1. U.S. District Court for the District of Delaware. (2021). Allergan, Inc. v. Revance Therapeutics, Inc., No. 1:21-cv-01411-RGA. PACER/RECAP docket materials.

2. U.S. Food and Drug Administration. (2022, September 8). FDA approves new treatment for adults with moderate to severe frown lines. https://www.fda.gov/

3. Revance Therapeutics, Inc. (2022-2024). Annual reports on Form 10-K and quarterly reports on Form 10-Q. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar.shtml